Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

461.71 -1.28 (-0.28%)

Streaming Delayed Price Updated: 10:53 AM EST, Dec 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

69 70 Next >

Could These 3 Companies Headline a "Magnificent Seven" of Biotech Stocks? ↗

February 29, 2024

These stocks meet many of the criteria long-term investors look for.

Via The Motley Fool

$100 Invested In This Stock 15 Years Ago Would Be Worth $1,500 Today ↗

February 27, 2024

Via Benzinga

Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug ↗

February 27, 2024

Both companies are working on treatments for genetic disorders.

Via Investor's Business Daily

3 Biotech Stocks Bound to Blast Off By 2029 ↗

February 27, 2024

Biotech stocks are risky, but rewarding. These three biotechs specifically could see exponential gains in the coming years.

Via InvestorPlace

bluebird bio: How to play LEAPS options for growth and income

February 27, 2024

Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT

Via MarketBeat

What Analysts Are Saying About Vertex Pharmaceuticals Stock ↗

February 20, 2024

Via Benzinga

Vertex Pharmaceuticals (VRTX) Should Remain Supported ↗

February 27, 2024

Vertex Pharmaceuticals Incorporated (VRTX), is a biotechnology company. It engages in developing & commercializing therapies for treating cystic fibrosis (CF).

Via Talk Markets

3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow ↗

February 27, 2024

Vertex shares have climbed almost 50% over the past year.

Via The Motley Fool

Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices ↗

February 26, 2024

Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs.

Via Benzinga

Is CRISPR Therapeutics the NVIDIA of gene editing?

February 26, 2024

CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv

Via MarketBeat

Topics Artificial Intelligence

The Ultimate Growth Stock to Buy With $1,000 Right Now ↗

February 26, 2024

The positives are many and the negatives are few with this high-flying stock.

Via The Motley Fool

2 Stocks That Could Crush the Market in 2024 ↗

February 25, 2024

These companies aren't slowing down, and their addressable markets are widening.

Via The Motley Fool

Three S&P 500 Giants Lead This List Of Stocks Near Buy Points ↗

February 24, 2024

Watch these five stocks, but the market is slightly extended.

Via Investor's Business Daily

Topics Stocks

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On. ↗

February 23, 2024

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

Via Investor's Business Daily

The Best Stocks to Invest $5,000 in Right Now ↗

February 23, 2024

These stocks could be huge winners for long-term investors.

Via The Motley Fool

3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024 ↗

February 22, 2024

With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.

Via InvestorPlace

3 Secret Stocks to Double Your Money by 2028 ↗

February 22, 2024

Vertex Pharmaceuticals (VRTX), UiPath (PATH), and Science Applications International (SAIC) are 3 secret stocks to double your money by 2028.

Via InvestorPlace

Vertex to Participate in Upcoming Investor Conferences

February 20, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Pharmaceuticals Is About to Extend Its Leadership in This Billion-Dollar Market ↗

February 20, 2024

Vertex's main business may be heading for a new era of growth...

Via The Motley Fool

Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought ↗

February 20, 2024

These exciting players could deliver explosive growth over time.

Via The Motley Fool

3 Revolutionary Biotech Stocks Poised for 10X Surge ↗

February 19, 2024

Discover three biotech stocks set to soar in a $3.08 trillion market, merging medical innovations with financial growth opportunities.

Via InvestorPlace

3 Magnificent Growth Stocks to Buy Right Now ↗

February 19, 2024

These stocks share at least two common denominators: a biopharmaceutical focus and great long-term prospects.

Via The Motley Fool

Could This News Upset Vertex Pharmaceuticals' Prospects in the Billion-Dollar Pain Management Market? ↗

February 18, 2024

The pain market is in great need of new options.

Via The Motley Fool

2 Top Growth Stocks to Buy With $1,000 Right Now ↗

February 18, 2024

Even a modest starting investment in the right stocks could pay off in the years ahead.

Via The Motley Fool

Vertex Pharmaceuticals Will Use $100 Million to Tank Its Own Market Share. Here's Why That's a Smart Move. ↗

February 17, 2024

Sometimes, the winning move doesn't look right at first.

Via The Motley Fool

2 Healthcare Growth Stocks That Are No-Brainer Buys Right Now ↗

February 17, 2024

The healthcare industry often remains resilient amid macro headwinds, and these two stocks are prime examples.

Via The Motley Fool

Giving Uber Its Due ↗

February 15, 2024

We've also got a look at good news from Chipotle and Roblox, and we put some stocks on a dating show.

Via The Motley Fool

Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade. ↗

February 15, 2024

These stocks have what it takes to drive superior returns in the years to come.

Via The Motley Fool

Gene therapy: Why does it cost millions for a single treatment?

February 15, 2024

Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.

Via MarketBeat

Is Vertex Pharmaceuticals Stock Too Expensive With a Price-to-Sales Ratio of 11x? ↗

February 15, 2024

There's more to consider with Vertex's valuation than one number.

Via The Motley Fool

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.